• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ELOVL6 通过生物信息学分析与肺腺癌的免疫抑制有关。

ELOVL6 is associated with immunosuppression in lung adenocarcinoma through bioinformatics analysis.

机构信息

The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.

出版信息

Medicine (Baltimore). 2023 Sep 8;102(36):e35013. doi: 10.1097/MD.0000000000035013.

DOI:10.1097/MD.0000000000035013
PMID:37682172
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10489423/
Abstract

The aim of this paper was to reveal the correlation between the expression of ELOVL fatty acid elongase 6 (ELOVL6) gene in lung adenocarcinoma (LUAD) and its clinical significance, immune cell infiltration level and prognosis. Expression profile data of ELOVL6 mRNA were collected from the cancer genome atlas database to analyze the differences in ELOVL6 mRNA expression in LUAD tissues and normal lung tissues, and to analyze the correlation between ELOVL6 and information on clinicopathological features. Based on TIMER database, TISDIB database and GEPIA2 database, the correlation between ELOVL6 expression and tumor immune cell infiltration in LUAD was analyzed. Gene ontology and Kyoto encyclopedia of genes and genomes enrichment analyses of ELOVL6-related co-expressed genes were performed to identify the involved signaling pathways and to construct their co-expressed gene protein interaction networks. Drugs affected by ELOVL6 expression were screened based on the Cell Miner database. These findings suggest that ELOVL6 plays an important role in the course of LUAD, and the expression level of this gene has a close relationship with clinicopathological characteristics and survival prognosis, and has the potential to become a prognostic marker and therapeutic target for LUAD.

摘要

本文旨在揭示肺腺癌(LUAD)中 ELOVL 脂肪酸延长酶 6(ELOVL6)基因的表达与其临床意义、免疫细胞浸润水平和预后之间的相关性。从癌症基因组图谱数据库中收集 ELOVL6 mRNA 的表达谱数据,以分析 LUAD 组织和正常肺组织中 ELOVL6 mRNA 表达的差异,并分析 ELOVL6 与临床病理特征信息之间的相关性。基于 TIMER 数据库、TISDIB 数据库和 GEPIA2 数据库,分析 ELOVL6 表达与 LUAD 肿瘤免疫细胞浸润的相关性。对 ELOVL6 相关共表达基因进行基因本体和京都基因与基因组百科全书富集分析,以确定涉及的信号通路,并构建其共表达基因蛋白相互作用网络。基于 Cell Miner 数据库筛选受 ELOVL6 表达影响的药物。这些发现表明,ELOVL6 在 LUAD 的发生发展过程中起着重要作用,该基因的表达水平与临床病理特征和生存预后密切相关,有望成为 LUAD 的预后标志物和治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/41c089f599b8/medi-102-e35013-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/7229eb1a0b06/medi-102-e35013-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/fd6bc75ea24a/medi-102-e35013-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/7e238650d061/medi-102-e35013-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/2f8af9e885ab/medi-102-e35013-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/3596bf25b816/medi-102-e35013-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/3f8e5e8b9924/medi-102-e35013-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/98fa6038c66a/medi-102-e35013-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/41c089f599b8/medi-102-e35013-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/7229eb1a0b06/medi-102-e35013-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/fd6bc75ea24a/medi-102-e35013-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/7e238650d061/medi-102-e35013-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/2f8af9e885ab/medi-102-e35013-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/3596bf25b816/medi-102-e35013-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/3f8e5e8b9924/medi-102-e35013-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/98fa6038c66a/medi-102-e35013-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1b/10489423/41c089f599b8/medi-102-e35013-g008.jpg

相似文献

1
ELOVL6 is associated with immunosuppression in lung adenocarcinoma through bioinformatics analysis.ELOVL6 通过生物信息学分析与肺腺癌的免疫抑制有关。
Medicine (Baltimore). 2023 Sep 8;102(36):e35013. doi: 10.1097/MD.0000000000035013.
2
Exploring the role of ELOVLs family in lung adenocarcinoma based on bioinformatic analysis and experimental validation.基于生物信息学分析和实验验证探索ELOVLs家族在肺腺癌中的作用
BMC Cancer. 2025 Jan 10;25(1):62. doi: 10.1186/s12885-024-13415-y.
3
EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.EZH2 作为肺腺癌中与细胞周期和免疫浸润相关的预后相关生物标志物。
BMC Bioinformatics. 2023 Apr 17;24(1):149. doi: 10.1186/s12859-023-05271-7.
4
Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.利用生物信息学方法鉴定 CDT1 作为人肺腺癌的预后标志物。
PeerJ. 2023 Sep 28;11:e16166. doi: 10.7717/peerj.16166. eCollection 2023.
5
[Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].[早期肺腺癌磨玻璃影微乳头成分的突变特征分析及ZNF469基因探索]
Zhongguo Fei Ai Za Zhi. 2024 Jan 2;26(12):889-900. doi: 10.3779/j.issn.1009-3419.2023.106.23. Epub 2023 Dec 28.
6
Elevated ADAR expression is significantly linked to shorter overall survival and immune infiltration in patients with lung adenocarcinoma.ADAR 表达升高与肺腺癌患者总生存期更短和免疫浸润显著相关。
Math Biosci Eng. 2023 Sep 20;20(10):18063-18082. doi: 10.3934/mbe.2023802.
7
In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma.计算机分析显示 PRR11 是肺腺癌的一个预后和致癌标志物。
Medicine (Baltimore). 2023 May 26;102(21):e33755. doi: 10.1097/MD.0000000000033755.
8
Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.预测涉及人肺腺癌进展的失调竞争内源性 RNA 特征。
Cancer Biomark. 2020;29(3):399-416. doi: 10.3233/CBM-200133.
9
High Expression of Is Associated with the Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma Patients.高表达与肺腺癌患者的不良预后和免疫浸润有关。
Dis Markers. 2022 Jul 9;2022:8789515. doi: 10.1155/2022/8789515. eCollection 2022.
10
HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.HMMR 与免疫浸润物相关,并作为肺腺癌的预后生物标志物。
Comput Biol Med. 2022 Dec;151(Pt A):106213. doi: 10.1016/j.compbiomed.2022.106213. Epub 2022 Oct 23.

引用本文的文献

1
Exploring the role of ELOVLs family in lung adenocarcinoma based on bioinformatic analysis and experimental validation.基于生物信息学分析和实验验证探索ELOVLs家族在肺腺癌中的作用
BMC Cancer. 2025 Jan 10;25(1):62. doi: 10.1186/s12885-024-13415-y.

本文引用的文献

1
An integrated bioinformatic analysis of bulk and single-cell sequencing clarifies immune microenvironment and metabolic profiles of lung adenocarcinoma to predict immunotherapy efficacy.对 bulk 和单细胞测序的综合生物信息学分析阐明了肺腺癌的免疫微环境和代谢特征,以预测免疫治疗疗效。
Front Cell Dev Biol. 2023 Apr 5;11:1163314. doi: 10.3389/fcell.2023.1163314. eCollection 2023.
2
Establishment of a Lymph Node Metastasis-Associated Prognostic Signature for Lung Adenocarcinoma.建立肺腺癌淋巴结转移相关预后特征。
Genet Res (Camb). 2023 Jan 31;2023:6585109. doi: 10.1155/2023/6585109. eCollection 2023.
3
Delineating the dynamic evolution from preneoplasia to invasive lung adenocarcinoma by integrating single-cell RNA sequencing and spatial transcriptomics.
通过整合单细胞 RNA 测序和空间转录组学,描绘从癌前病变到浸润性肺腺癌的动态演变过程。
Exp Mol Med. 2022 Nov;54(11):2060-2076. doi: 10.1038/s12276-022-00896-9. Epub 2022 Nov 25.
4
Characterizing and Targeting Genes Regulated by Transcription Factor MYBL2 in Lung Adenocarcinoma Cells.鉴定和靶向肺腺癌细胞中转录因子MYBL2调控的基因
Cancers (Basel). 2022 Oct 11;14(20):4979. doi: 10.3390/cancers14204979.
5
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.三阴性乳腺癌化疗耐药和化疗反应的蛋白质基因组标志物。
Cancer Discov. 2022 Nov 2;12(11):2586-2605. doi: 10.1158/2159-8290.CD-22-0200.
6
plays a significant prognostic role in lung adenocarcinoma and is associated with tumor immunity based on bioinformatics analysis.基于生物信息学分析,其在肺腺癌中发挥着重要的预后作用,并与肿瘤免疫相关。
Ann Transl Med. 2022 May;10(9):519. doi: 10.21037/atm-22-1430.
7
GPR87 promotes tumor cell invasion and mediates the immunogenomic landscape of lung adenocarcinoma.GPR87 促进肿瘤细胞侵袭,并介导肺腺癌的免疫基因组图谱。
Commun Biol. 2022 Jul 5;5(1):663. doi: 10.1038/s42003-022-03506-6.
8
TCN1 is a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma.TCN1 是肺腺癌的一个潜在预后生物标志物,与免疫浸润相关。
World J Surg Oncol. 2022 Mar 14;20(1):83. doi: 10.1186/s12957-022-02556-8.
9
The chemotherapeutic drug carboplatin affects macrophage responses to LPS and LPS tolerance via epigenetic modifications.化疗药物卡铂通过表观遗传修饰影响巨噬细胞对 LPS 的反应和 LPS 耐受。
Sci Rep. 2021 Nov 3;11(1):21574. doi: 10.1038/s41598-021-00955-7.
10
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.针对非小细胞肺癌(NSCLC)中的 HER2:一线希望?HER2 改变 NSCLC 的治疗策略更新综述。
ESMO Open. 2021 Oct;6(5):100260. doi: 10.1016/j.esmoop.2021.100260. Epub 2021 Aug 31.